跳至主要内容
临床试验/NCT04575337
NCT04575337招募中不适用

Study on Body Fluid, Gene and Neuroimaging Biomarkers for Early Diagnosis of Alzheimer's Disease

Capital Medical University1 个研究点 分布在 1 个国家目标入组 6,000 人开始时间: 2020年5月28日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
6,000
试验地点
1
主要终点
A multiple diagnostic kit for early diagnosis of AD.

研究概览

简要总结

The project of Bio-AD is a population- based cohort study among the elderly in China.

The project includes not only Alzheimer's disease (AD including familial AD and sporadic AD), but also other clinical stage of AD, as well as elderly people with normal cognitive function.

The project will collect, detect and screen the special biomarkers at different clinical stage of AD based on body fluid, gene and brain image. The standard and consistent assessment protocols are employed to obtain clinical, cognitive, genetic, neuroimaging and biospecimen data.

The purpose of this project is to establish a panel of biomarkers which could be used to diagnose AD at the early stage, and to establish a risk prediction models for AD to predict the 5-years risk of the onset and progression of AD among elderly population in China.

详细描述

  1. Set up a large population- based cohort including AD, MCI, pre-MCI, other neurodegenerative diseases, and elderly individuals with normal cognitive function.
  2. Collect the information of clinical and neuropsychological assessment, individual traits and social environmental factors, and neuroimaging data, as well as the biological samples, such as peripheral blood and cerebrospinal fluid.
  3. Screen biomarkers with high specificity and sensitivity from peripheral blood, cerebrospinal fluid and neuroimaging to distinguish different clinical stages of AD at baseline.
  4. Screen the AD-associated gene and their risk variants.
  5. Establish a panel of AD-specific biomarkers for the preliminary development of diagnostic kit.
  6. Identify AD-relevant factors and the special biomarkers to create a preliminary risk models to predict the onset and progression of AD.
  7. Follow up the cohort for next 5 years and collect the multiple information and biological samples each year to validate and revise the risk prediction models and the diagnostic kit of AD.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Written informed consent obtained from participant or legal guardian prior to any study-related procedures.
  • Aged 18 (inclusive) or older.
  • Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-R). The diagnosis of AD is made using the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS- ADRDA) or National Institute on Aging and the Alzheimer's Assocation (NIA-AA) criteria. A diagnosis of mild cognitive impairment (MCI) is assigned according to Petersen criteria. A diagnosis of pre-MCI group is assigned by β-Amyloid positive or APOE ε4 carrier or complains of cognitive impairment, but not up to MCI or cognitive impairment. Normal cognitive function assessed/evaluated by MMSE, CDR and other cognitive function scales.
  • Follow up 5 years and collect the information.

排除标准

  • Under age
  • Medical or psychiatric illness that would interfere in completing initial and follow-up visits.
  • No one can serve as a study informant.
  • With current or past neurological or psychiatric illnesses such as schizophrenia, epilepsy, brain tumors, severe head trauma and other diseases which can induce dementia.
  • Refused to complete a cognitive test and provide biospecimen.
  • With history of alcohol or drug abuse.

结局指标

主要结局

A multiple diagnostic kit for early diagnosis of AD.

时间窗: An Average of 1 year

A panel of special biomarkers is identified for early diagnosis of AD.

A 5-years risk prediction model for onset and progression of AD among elderly population in China.

时间窗: An Average of 1 year

A 5-years risk prediction model including multiple factors to predict the onset and progression of AD in China.

次要结局

  • A panel of biomarker with high specificity and sensibility(An Average of 1 year)
  • AD-associated genes in Chinese.(An Average of 1 year)
  • Neuroimaging biomarkers for AD(An Average of 1 year)
  • Risks and protective factors for AD among elderly in China(An Average of 1 year)

研究者

发起方
Capital Medical University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Jianping Jia

Chief Director

Capital Medical University

研究点 (1)

Loading locations...

相似试验